Exploring Hereditary Cancer Among Dying Cancer Patients—A Cross-Sectional Study of Hereditary Risk and Perceived Awareness of DNA Testing and Banking
Hereditary cancer assessment at the end of life is a relatively unexplored area, but it could be critical for surviving family members. This study explored the prevalence of hereditary cancer among dying cancer patients and assessed patients’ perceived awareness of DNA testing and/or banking in a public access hospital. Palliative care patients with cancer from a single institution (or their medical-decision-making surrogates for patients unable to answer for themselves) completed structured interviews. Information was collected through medical records review and structured interviews for 43 dying cancer patients. Information for 9 patients was collected from surrogates. Nine patients (21%, 95% CI = 8.8% to 33.1%) had strong genetic risk. Currently available genetic tests could have addressed this risk for several patients. None had previous genetic counseling, testing or DNA banking. Among strong-risk patients, about half of patients/surrogates had heard/read “almost nothing” about genetic testing (44%) and DNA banking (67%). Perceived genetic awareness was not associated with genetic risk, and neither were sociodemographic characteristics. The proportion of hereditary cancer may be at least as high in the palliative care population as in other clinical settings, but awareness and uptake among patients are low. These conditions are not being recognized upstream and families are losing valuable information.
KeywordsHereditary Neoplasm Cancer Genetic screening DNA banking End of life Genetic testing Genetic counseling
Funding for this study was from the Massey Cancer Center at Virginia Commonwealth University. We would like to thank Ms. Funmi Obiri for recruitment and administrative assistance.
- Durfy, S. J., Bowen, D. J., McTiernan, A., Sporleder, J., & Burke, W. (1999). Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in western Washington. Cancer Epidemiology, Biomarkers & Prevention, 4(Pt 2), 369–375.Google Scholar
- Fowler, E. S., Neese, E. R., & Schwartzberg, L. S. (2005). Cancer genetic counseling: trends in patient referrals and genetic testing in a community-based program. Community Oncology, 3, 253–260.Google Scholar
- National Comprehensive Cancer Network (2008). Practice Guidelines in Oncology. Genetic/Familial High Risk Assessment: Breast and Ovarian Cancer. V.1.2008.Google Scholar
- Offit, K. (1998). Clinical cancer genetics. New York: Wiley-Liss, Inc.Google Scholar
- Palomaki, G. E., McClain, M. R., Steinort, K., Sifri, R., LoPresti, L., & Haddow, J. E. (2006). Screen-positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a population-based cohort of 21- to 55-year-old women. Genetics in Medicine, 8, 161–8.CrossRefPubMedGoogle Scholar
- Prochaska, J. O., & DiClemente, C. C. (2005). The transtheoretical approach. In J. C. Norcross & M. R. Goldfried (Eds.), Handbook of psychotherapy integration (2nd ed., pp. 147–171). New York: Oxford University Press.Google Scholar
- U.S. Preventive Services Task Force. (2005). Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Annals of Internal Medicine, 5, 355–361.Google Scholar
- Wooster, R., & Weber, B. L. (2003). Breast and ovarian cancer. The New England Journal of Medicine, 23, 2339–2347.Google Scholar